Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Neurogene Inc. (NGNE : NSDQ)

• Company Description    Neurogene Inc. is a clinical-stage company which bring life-changing genetic medicines to patients and families affected by rare neurological diseases. Neurogene Inc., formerly known as Neoleukin Therapeutics Inc., is based in NEW YORK. Number of Employees: 107

• Price / Volume Information    Yesterday's Closing Price: $21.96 Daily Weekly Monthly 20 Day Moving Average: 212,169 shares Shares Outstanding: 14.26 (millions) Market Capitalization: $313.20 (millions) Beta: 1.51 52 Week High: $74.49 52 Week Low: $6.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.65% 3.62% 12 Week 91.12% 60.76% Year To Date -3.94% -10.04%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 535 W 24TH STREET 5TH FLOOR - NEW YORK,NY 10011 USA ph: 855-508-3568 fax: 778-331-4486 neurogene@argotpartners.com http://www.neurogene.com

• General Corporate Information    Officers Rachel McMinn - Chief Executive Officer Christine Mikail - President and Chief Financial Officer Robert Baffi - Director Cory Freedland - Director Sarah B. Noonberg - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 64135M105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 14.26 Most Recent Split Date: 12.00 (0.25:1) Beta: 1.51 Market Capitalization: $313.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.81 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.07 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -8.00% vs. Previous Quarter: -9.09% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -36.16 12/31/24 - -38.85 ROA 06/30/25 - - 03/31/25 - -32.51 12/31/24 - -34.35 Current Ratio 06/30/25 - - 03/31/25 - 21.03 12/31/24 - 20.84 Quick Ratio 06/30/25 - - 03/31/25 - 21.03 12/31/24 - 20.84 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - -8,742.70 12/31/24 - -8,123.68 Book Value 06/30/25 - - 03/31/25 - 20.46 12/31/24 - 20.89 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.01

Powered by Zacks Investment Research ©